How were Cardiome Pharma's earnings last quarter?

Cardiome Pharma Corp (NASDAQ:CRME) posted its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company earned $6.54 million during the quarter, compared to analyst estimates of $7.34 million.

What other stocks do shareholders of Cardiome Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiome Pharma investors own include Energy Transfer (ET) , CBL & Associates Properties (CBL) , Cornerstone Strategic Value Fund (CLM) , Cornerstone Total Return Fund (CRF) , SandRidge Permian Trust (PER) , SunCoke Energy Partners (SXCP) , Martin Midstream Partners (MMLP) , Navios Maritime Midstream Partners (NAP) , C3.ai (AI) and Government Properties Income Trust (GOV) .

NASDAQ:CRME

Cardiome Pharma (CRME) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CRME Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $2.30
▼
$2.45
50-Day Range: N/A
52-Week Range: $1.29
▼
$4.84

Volume: 90,444 shs
Average Volume: 135,322 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Cardiome Pharma alerts:

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

About Cardiome Pharma Stock (NASDAQ:CRME)

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. The company also provides ESMOCARD and ESMOCARD LYO short-acting beta-blockers used to control rapid heart rate; XYDALBA, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections; and TREVYENT for the treatment of pulmonary arterial hypertension. It has operations in Canada, the United States, Europe, and internationally. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

Ad Paradigm Press

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS

Click here to find out that this 8,788% cryptocurrency is.

CRME Stock News Headlines

August 13, 2023 | nasdaq.com

Amphastar Pharmaceuticals (FRA:29A) Price Target Increased by 46.10% to 60.45

March 25, 2023 | marketwatch.com

Expert Analysis on Pharmaceutical Rubber Stoppers Market by 2023-2030

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

February 17, 2023 | msn.com

Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg

February 12, 2023 | msn.com

Pharmacy Career Conference returned in its 4th edition to assist and inspire pharmacy students and industry professionals

February 1, 2023 | msn.com

Pharma sector growth healthy after Covid too

December 29, 2022 | cbsnews.com

DOJ sues pharma giant AmerisourceBergen Corp. for allegedly helping to fuel the opioid epidemic

November 2, 2022 | marketwatch.com

Acute Coronary Syndrome Therapeutics Market Size in Pharma & Healthcare Sector is Growing Quickly with Analysis by Top Key players till 2028

April 19, 2024 | TradeSmith (Ad)

The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

October 20, 2022 | yahoo.com

Pharmaceutical Fine Chemicals Category Is Projected to Grow at a CAGR of 5.86% by 2026, SpendEdge Reports

October 13, 2022 | finance.yahoo.com

Jenny Sundqvist new CEO of InDex Pharmaceuticals

September 28, 2022 | benzinga.com

1SOMAÍ Pharmaceuticals Opens Medical Cannabis Manufacturing Facility In Portugal

September 13, 2022 | msn.com

NLEM 2022 | Govt releases new list of 384 essential medicines; 34 drugs added, 26 dropped

September 13, 2022 | msn.com

Macleods Pharmaceuticals defers big-bang listing plans; will PE funds step in now?

August 30, 2022 | marketwatch.com

Cardiac Rhythm Management Devices Market [4.5% CAGR] 2022 Industry Research Analysis Opportunities Key Players Analysis And Forecast By 2028

October 26, 2021 | finance.yahoo.com

Cardiome Pharma Corp. Announces Approximately US$15.0 Million Bought Deal Financing

See More Headlines

Receive CRME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiome Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2018
Today: 4/19/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CRME
CUSIP: N/A
CIK: 1036141
Web: www.cardiome.com
Phone: 604-677-6905
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Dr. William L. Hunter (Age 55)
Pres, CEO & Director
Ms. Sheila M. Grant MBA
Chief Operating Officer
Mr. David D. McMasters (Age 59)
Gen. Counsel
Mr. Hugues Sachot
Chief Commercial Officer
Mr. Justin A. Renz (Age 46)
Chief Financial Officer

Key Competitors

View All Competitors

CRME Stock Analysis - Frequently Asked Questions

How were Cardiome Pharma's earnings last quarter?: Cardiome Pharma Corp (NASDAQ:CRME) posted its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.02. The biopharmaceutical company earned $6.54 million during the quarter, compared to analyst estimates of $7.34 million.
What other stocks do shareholders of Cardiome Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiome Pharma investors own include Energy Transfer (ET), CBL & Associates Properties (CBL), Cornerstone Strategic Value Fund (CLM), Cornerstone Total Return Fund (CRF), SandRidge Permian Trust (PER), SunCoke Energy Partners (SXCP), Martin Midstream Partners (MMLP), Navios Maritime Midstream Partners (NAP), C3.ai (AI) and Government Properties Income Trust (GOV).

This page (NASDAQ:CRME) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cardiome Pharma (CRME) Stock Price, News & Analysis

About Cardiome Pharma Stock (NASDAQ:CRME)

CRME Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

CRME Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info